TherapeuticsMD TXMD
NASDAQ TXMD
$1.85 -0.05 (-2.63%)
At close: Oct 22, 2026 · 4:00 PM EDT

TherapeuticsMD (TXMD) Gains from Sales and Divestitures (2022)

Updated

TherapeuticsMD (TXMD) reported Gains from Sales and Divestitures of $143.38 million for Q2 2022.

Analysis

TherapeuticsMD (TXMD) Gains from Sales and Divestitures (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn
10 TherapeuticsMD 21.12 Mn 21.12 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 143.38 Mn
API Access

TherapeuticsMD Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=TXMD&period=max&api_key=YOUR_API_KEY